Opinion

Video

Biologic Options in Pediatric Asthma

Author(s):

Nicole Chase, MD, FAAP, FACAAI, FAAAAI,S. Shahzad Mustafa, MD

The panel discusses the biologic drugs approved for use in children with asthma, including omalizumab, dupilumab, mepolizumab, and the recently approved benralizumab. They share their preferences among these options for improving lung function in pediatric patients.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Physician, Patient, and Partner Perspectives on AERD with Mitchell Grayson, MD, Rhonda Nelson, and Wayne Nelson
Monica Kraft, MD: Discussing Phase 3b Findings on Albuterol/Budesonide for Asthma
Related Content
First Fungal Spore Calendar Developed for Patients with Asthma, Allergies
November 14th 2024

First Fungal Spore Calendar Developed for Patients with Asthma, Allergies

Tim Smith
Checking in on the Lung Health Cohort Trial
October 29th 2024

Checking in on the Lung Health Cohort Research Study

Kevin Kunzmann
Lauren Roland, MD, MSCI | Credit: Washington University
October 16th 2024

Functional Endoscopic Sinus Surgery Efficacious for Comorbid Chronic Rhinosinusitis, Asthma

Abigail Brooks, MA
Lung Imaging 2.0: How AI is Shaping the Future with Rachel Eddy, PhD
September 30th 2024

Lung Imaging 2.0: How AI is Shaping the Future with Rachel Eddy, PhD

Kevin Kunzmann
Helping Schools Calculate Respiratory Infection Risk
September 16th 2024

Helping Schools Calculate Respiratory Infection Risk

Amanda Wilson, PhD Ashley Lowe, PhD, MSPH Lynn B. Gerald, PhD, MSPH
FDA Approves Dupilumab for Adolescents with Chronic Rhinosinusitis with Nasal Polyps
September 13th 2024

FDA Approves Dupilumab for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Tim Smith
© 2024 MJH Life Sciences

All rights reserved.